Latest Hyperphosphatemia News
A low protein, low phosphorus diet plays an important role in the nutritional management of patients transitioning to once-weekly incremental hemodialysis.
Hyperphosphatemia was associated with more than double the risk of death from any cause.
Patients reduced dietary phosphorus without compromising protein intake.
The USDA Standard Nutrient Reference Database, for example, listed phosphorus amounts for just 5 of 46 beverages.
For each 1 mmol/L increase in serum phosphorus, the odds of left ventricular hypertrophy more than doubled.
Calcium-based binders, however, are associated with greater odds of all-cause mortality versus sevelamer.
In a study, 61% of hemodialysis patients reported accidentally forgetting to take their medication or otherwise skipping doses unintentionally.
Over 33 months, the 25-hydroxyvitamin D level of ergocalciferol recipients increased significantly from 15.14 to 37.32 ng/mL.
Researchers evaluated the efficacy of 100 mg/day of niacin in hemodialysis patients.
The phosphate binder is a useful treatment for hyperphosphatemia with a relatively low pill burden, researchers say.
Patients may need no more than routine evaluation of iron.
Phosphorus targets in patients with chronic kidney disease stage 3 to 4 should be below 4.3 mg/dL, researchers report.
Hyperphosphatemia is present in many who say following diets and binder schedules is easy.
Autonomy support could be an appropriate target for culturally informed strategies to optimize mineral bone health.
A mortality rate increase of 43 cases per 1000 patients was found for calcium-based phosphate binders.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)